News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

Compressive Sensing Could Dramatically Reduce Time to Process Complex Clinical Laboratory Tests Involving Huge Amounts of Data and Lower the Cost of Tests

Experts believe compressive sensing could find wide application in medical laboratory and pathology testing, particularly where large amounts of data are generated

Pathologists and medical laboratory managers may soon be working with a new tool in their labs. It is called “Compressive Sensing” (CS) and it is an innovative mathematical approach that quickly and efficiently gets an answer by sampling large volumes of a data.

Currently compressive sensing is used in medical imaging technology. CS reduces radiation and speeds up imaging diagnostics. Some experts familiar with this technology believe that it can be used in those clinical laboratories that are working with new diagnostic technologies that generate large volumes of data. CS could dramatically reduce times to analyze results and lower the cost of expensive tests like whole-genome sequencing. (more…)

Consumers May Soon Have a Home Blood Collection Kit That Allows Them to Monitor and Quantify Damage to Their DNA

Exogen uses crowdfunding to both collect needed specimens and raise capital to pursue FDA clearance for its proposed medical laboratory test that would identify an individual’s damaged DNA

It might be coming soon to a pharmacy or other retail store near you: a medical laboratory test kit allows consumers to test themselves for damaged DNA. This bold new world for genetic testing is the vision of a new company in San Francisco called Exogen Biotechnology.

This startup business was co-founded by Sylvain Costes, Ph.D., a nuclear engineer who serves as Exogen’s Chief Executive Officer, and Jonathan Tang, Ph.D., a bioengineer. Their team is developing a blood test that will enable consumers to monitor their own DNA damage and take actions to reverse the damage. (more…)

Mayo Clinic and Whole Biome Announce Collaboration to Research the Role of the Human Microbiome in Women’s Diseases Using Unique Medical Laboratory Tests

This joint research effort will initiate a new field of clinical laboratory diagnostic tests that target the human microbiome

Mayo Clinic Center for Individualized Medicine is about to commence clinical trials utilizing innovative clinical laboratory tests that target the human microbiome. Women’s health is the initial focus for these clinical studies.

Mayo Clinic is collaborating with San Francisco-based Whole Biome, Inc., to conduct these clinical trials. Whole Biome developed the diagnostic tests to be used in the clinical study. (more…)

Might Pathologists Soon Have a Medical Laboratory Test Capable of Predicting a Patient’s Probability of Death within Five Years?

Researchers in Finland have discovered four biomarkers in blood that appear to accurately identify individuals at high-risk of death in the short term 

Will there be demand for a medical laboratory test that can help pathologists accurately predict the probability of death within five years for an individual? New research emerging from Europe suggests that such a diagnostic assay may be feasible.

More remarkable, this clinical laboratory test may be as simple as testing for the concentration of four biomarkers in blood. In combination, these biomarkers indicate the status of metabolism in all humans that can possibly predict when an individual will die. According to researchers, their relative amounts are crucial to determining if an individual is at high risk for death within five years. (more…)

Researchers at Columbia University Report How Exome Sequencing Helped Diagnose Patients with Unknown Disorders

More precise diagnoses will encourage pathologists and clinical laboratory professionals to consider using exome sequencing for clinical diagnostic purposes

Having sequenced the exomes of 150 patients to diagnose unknown disorders over the past year, physicians at Columbia University (CU) used that information to make decisive diagnoses in one-third of the cases. It is evidence from one of the nation’s pioneering gene-sequencing programs that such data can improve how physicians identify disease.

Findings from Exome Sequencing Program Noteworthy for Pathologists

Pathologists will find it noteworthy that some of the patients in the exome-sequencing program had been tracked for years at CU without a definitive diagnosis. This is why clinicians at the academic center in New York City see value in exome sequencing for selected patients.

For more than a year, doctors at Columbia University have tested the exome’s capability to provide a correct diagnosis for patients with suspected genetic disorders of unknown origins. The primary goal of the program is to prove that sequencing the exomes of these patients is both clinically useful and cost effective in guiding physicians to a correct diagnosis. (more…)